Contraception for adolescents with chronic rheumatic diseases

Benito Lourenço, Kátia Tomie Kozu, Gabriela Nunes Leal, Marco F. Silva, Elisabeth Gonzaga Canova Fernandes, Camila M.P. França, Fernando Henrique Carlos de Souza, Clóvis A. Silva
In: Revista Brasileira de Reumatologia (English Edition) · 2016 · vol. 57(1) , pp. 73–81 · doi:10.1016/j.rbre.2016.07.016 · PMID:28137405 · W2510495569
review OA: hybrid CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher

Abstract

Contraception is an important issue and should be a matter of concern in every medical visit of adolescent and young patients with chronic rheumatic diseases. This narrative review discusses contraception methods in adolescents with juvenile systemic lupus erythematosus (JSLE), antiphospholipid syndrome (APS), juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM). Barrier methods are safe and their use should be encouraged for all adolescents with chronic rheumatic diseases. Combined oral contraceptives (COC) are strictly prohibited for JSLE and APS patients with positive antiphospholipid antibodies. Reversible long-acting contraception can be encouraged and offered routinely to the JSLE adolescent patient and other rheumatic diseases. Progestin-only pills are safe in the majority of rheumatic diseases, although the main concern related to its use by adolescents is poor adherence due to menstrual irregularity. Depot medroxyprogesterone acetate injections every three months is a highly effective contraception strategy, although its long-term use is associated with decreased bone mineral density. COC or other combined hormonal contraceptive may be options for JIA and JDM patients. Oral levonorgestrel should be considered as an emergency contraception method for all adolescents with chronic rheumatic diseases, including patients with contraindication to COC.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (61)

Source provenance

openalex
last seen: 2026-05-11T06:17:40.080092+00:00
License: CC0 · commercial use OK